Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 152

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 152
---
.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

NOTE 6 – STOCKHOLDERS’ EQUITY (Cont.)

| d. | In August 2021, the Company’s board of directors and the holders of a majority of the Company’s                                          
 outstanding voting stock approved an amendment to the Company’s certificate of incorporation to amend the Certificate of Designation     
 of Rights relating to the Series B Preferred Stock, par value $0.001 per share, to adjust the conversion rate thereunder from 500 shares 
 of Common Stock to each share of Series B Preferred Stock to eight (8) shares of Common Stock to each share of Series B Preferred Stock  
 and (ii) to delete the authorized Preferred Stock of the Company.                                                                        |

In connection with the above, in August
2021 the holders of the 2 million outstanding preferred stock agreed to convert all of the outstanding preferred shares into 16 million
shares of Common Stock immediately following the filing with the State of Delaware of the amendment to the certificate of incorporation.

On November 1, 2021, the Company amended
its certificate of incorporation to amend the Certificate of Designation of Rights relating to the Series B Preferred Stock, par value
$0.001 per share, to adjust the conversion rate thereunder from 500 shares of Common Stock to each share of Series B Preferred Stock to
eight (8) shares of Common Stock to each share of Series B Preferred Stock (the “Amendment to Series B Designations”).

On November 30, 2021, the then outstanding
2,000,000 million shares of Series B Preferred Stock, par value $0.001 per share converted into 16 million shares of the Company’s
Common Stock.

| e. | On August 16, 2022, the Company received $375 from the private placement of units of the Company ‘securities                                
 where each unit (a “Unit” and collectively the “Units”) is comprised of (i) two (2) share of the Company’s                                  
 Common Stock and (ii) one common stock purchase warrant to purchase an additional share of the Company’s Common Stock through December      
 9, 2023 at a per share exercise price of $0.80 through August 16, 2025. The price per Unit was $0.80. In consideration thereof, in November 
 2022 the investor was issued 937,500 shares of Common